Skip to main content
Clinical Trials/NCT05570071
NCT05570071
Not yet recruiting
Not Applicable

A Randomized Controlled Clinical Study of the Use of Vaginal Radiofrequency Therapy in Treatment of Stress Urinary Incontinence.

Qianfoshan Hospital0 sites90 target enrollmentOctober 20, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Urinary Incontinence, Stress
Sponsor
Qianfoshan Hospital
Enrollment
90
Primary Endpoint
Urine leakage in 1-hour pad test
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

To investigate the immediate, short-term and long-term efficacy of vaginal radiofrequency therapy in the treatment of stress urinary incontinence, and to compare the efficacy of pelvic floor electromyography combined with biofeedback therapy in stress urinary incontinence.

Detailed Description

Before treatment, patients with mild and moderate stress urinary incontinence were diagnosed according to the diagnostic criteria through medical history inquiry and gynecological physical examination, and patients were screened according to the inclusion and exclusion criteria. After informing two treatment plans and signing the informed consent, they were randomly divided into vaginal radiofrequency therapy group and electrical stimulation combined biofeedback group. After being included in the test, one hour urine pad test was conducted, and IIQ-7, PISQ-12 and FSFI questionnaires were completed. IIQ-7, PISQ-12 and FSFI questionnaires were followed up 1, 3, 6 and 12 months after treatment. After 3 months and 1 year of treatment, 1 hour urine pad test was given again.

Registry
clinicaltrials.gov
Start Date
October 20, 2022
End Date
March 31, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Qianfoshan Hospital
Responsible Party
Principal Investigator
Principal Investigator

Li Yan

pfofessor

Qianfoshan Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-75 years old women with a sexual history, and patients with mild to moderate stress urinary incontinence.

Exclusion Criteria

  • Severe cardiopulmonary insufficiency, acute pelvic inflammatory disease or other infectious stage, non-steroidal anti-inflammatory drugs and steroid hormones affecting collagen production factors, POP-Q-2 and above prolapse.

Outcomes

Primary Outcomes

Urine leakage in 1-hour pad test

Time Frame: before therapy

measure the urine leakage in 1-hour pad test

Change from urine leakage at 3 months

Time Frame: 3months after therapy

measure the urine leakage in 1-hour pad test at 3 months

Change from urine leakage at 12 months

Time Frame: 12months after therapy

measure the urine leakage in 1-hour pad test at 12 months

Secondary Outcomes

  • incontinence impact questionnaire short form,IIQ-7(12months after therapy)
  • pelvic organ prolapsed-incontinence sexual questionnaire, PISQ-12(12months after therapy)
  • Female Sexual index,FSFI(12months after therapy)

Similar Trials